Main variables;Main activity, secondary one or a tool necessary for production;Total
Companies that carry out R&D in Biotechnology;Total;1,299
Companies that carry out R&D in Biotechnology;Main;559
Companies that carry out R&D in Biotechnology;Secondary dwellings;230
Companies that carry out R&D in Biotechnology;Tool;510
%Companies according to biotechnology used: Genetic code;Total;30.8
%Companies according to biotechnology used: Genetic code;Main;39.2
%Companies according to biotechnology used: Genetic code;Secondary dwellings;31.4
%Companies according to biotechnology used: Genetic code;Tool;21.3
%Companies according to biotechnology used: Functional units;Total;38.4
%Companies according to biotechnology used: Functional units;Main;45.7
%Companies according to biotechnology used: Functional units;Secondary dwellings;43.0
%Companies according to biotechnology used: Functional units;Tool;28.3
%Companies according to biotechnology used: Cellular and tissue culturing and engineering;Total;21.5
%Companies according to biotechnology used: Cellular and tissue culturing and engineering;Main;26.3
%Companies according to biotechnology used: Cellular and tissue culturing and engineering;Secondary dwellings;19.8
%Companies according to biotechnology used: Cellular and tissue culturing and engineering;Tool;17.1
%Companies according to biotechnology used: Bioprocesses;Total;50.8
%Companies according to biotechnology used: Bioprocesses;Main;40.7
%Companies according to biotechnology used: Bioprocesses;Secondary dwellings;54.3
%Companies according to biotechnology used: Bioprocesses;Tool;60.2
%Companies according to biotechnology used: Sub-cellular organisms;Total;8.5
%Companies according to biotechnology used: Sub-cellular organisms;Main;12.7
%Companies according to biotechnology used: Sub-cellular organisms;Secondary dwellings;4.6
%Companies according to biotechnology used: Sub-cellular organisms;Tool;5.6
%Companies according to biotechnology used: Bio-computing;Total;24.0
%Companies according to biotechnology used: Bio-computing;Main;34.7
%Companies according to biotechnology used: Bio-computing;Secondary dwellings;22.1
%Companies according to biotechnology used: Bio-computing;Tool;13.2
%Companies according to biotechnology used: Nanobiotechnology;Total;12.1
%Companies according to biotechnology used: Nanobiotechnology;Main;15.6
%Companies according to biotechnology used: Nanobiotechnology;Secondary dwellings;15.6
%Companies according to biotechnology used: Nanobiotechnology;Tool;6.6
%Companies according to biotechnology used: Other;Total;16.9
%Companies according to biotechnology used: Other;Main;19.2
%Companies according to biotechnology used: Other;Secondary dwellings;20.6
%Companies according to biotechnology used: Other;Tool;12.7
%Company by field(s) of ultimate application of biotechnology use: Human Health;Total;45.5
%Company by field(s) of ultimate application of biotechnology use: Human Health;Main;64.2
%Company by field(s) of ultimate application of biotechnology use: Human Health;Secondary dwellings;36.9
%Company by field(s) of ultimate application of biotechnology use: Human Health;Tool;28.8
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture;Total;15.5
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture;Main;17.4
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture;Secondary dwellings;16.0
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture;Tool;13.1
%Company by field(s) of ultimate application of biotechnology use: Food products;Total;32.3
%Company by field(s) of ultimate application of biotechnology use: Food products;Main;21.0
%Company by field(s) of ultimate application of biotechnology use: Food products;Secondary dwellings;34.5
%Company by field(s) of ultimate application of biotechnology use: Food products;Tool;43.8
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production;Total;23.8
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production;Main;20.7
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production;Secondary dwellings;30.9
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production;Tool;23.9
%Company by field(s) of ultimate application of biotechnology use: Environment;Total;15.6
%Company by field(s) of ultimate application of biotechnology use: Environment;Main;14.1
%Company by field(s) of ultimate application of biotechnology use: Environment;Secondary dwellings;24.0
%Company by field(s) of ultimate application of biotechnology use: Environment;Tool;13.5
%Company by field(s) of ultimate application of biotechnology use: Industry;Total;13.7
%Company by field(s) of ultimate application of biotechnology use: Industry;Main;14.7
%Company by field(s) of ultimate application of biotechnology use: Industry;Secondary dwellings;18.5
%Company by field(s) of ultimate application of biotechnology use: Industry;Tool;10.6
Personnel in R&D in biotechnology (no. of persons);Total;15,750
Personnel in R&D in biotechnology (no. of persons);Main;6,759
Personnel in R&D in biotechnology (no. of persons);Secondary dwellings;3,644
Personnel in R&D in biotechnology (no. of persons);Tool;5,347
Personnel in R&D in biotechnology (no. of persons): Research personnel;Total;8,379
Personnel in R&D in biotechnology (no. of persons): Research personnel;Main;3,802
Personnel in R&D in biotechnology (no. of persons): Research personnel;Secondary dwellings;2,145
Personnel in R&D in biotechnology (no. of persons): Research personnel;Tool;2,433
Personnel in R&D in biotechnology (no. of persons): Technical and auxiliary personnel;Total;7,371
Personnel in R&D in biotechnology (no. of persons): Technical and auxiliary personnel;Main;2,957
Personnel in R&D in biotechnology (no. of persons): Technical and auxiliary personnel;Secondary dwellings;1,500
Personnel in R&D in biotechnology (no. of persons): Technical and auxiliary personnel;Tool;2,914
Personnel in R&D in biotechnology (no. of persons). Women;Total;8,711
Personnel in R&D in biotechnology (no. of persons). Women;Main;3,890
Personnel in R&D in biotechnology (no. of persons). Women;Secondary dwellings;2,040
Personnel in R&D in biotechnology (no. of persons). Women;Tool;2,782
Personnel in R&D in biotechnology (no. of persons). Women: Research personnel;Total;4,510
Personnel in R&D in biotechnology (no. of persons). Women: Research personnel;Main;2,078
Personnel in R&D in biotechnology (no. of persons). Women: Research personnel;Secondary dwellings;1,196
Personnel in R&D in biotechnology (no. of persons). Women: Research personnel;Tool;1,236
Personnel in R&D in biotechnology (no. of persons). Women: Technical and auxiliary personnel;Total;4,200
Personnel in R&D in biotechnology (no. of persons). Women: Technical and auxiliary personnel;Main;1,811
Personnel in R&D in biotechnology (no. of persons). Women: Technical and auxiliary personnel;Secondary dwellings;843
Personnel in R&D in biotechnology (no. of persons). Women: Technical and auxiliary personnel;Tool;1,546
Personnel in R&D in biotechnology (FTE);Total;11,528.6
Personnel in R&D in biotechnology (FTE);Main;5,389.0
Personnel in R&D in biotechnology (FTE);Secondary dwellings;2,417.3
Personnel in R&D in biotechnology (FTE);Tool;3,722.4
Personnel in R&D in biotechnology (FTE): Research personnel;Total;6,342.7
Personnel in R&D in biotechnology (FTE): Research personnel;Main;3,157.0
Personnel in R&D in biotechnology (FTE): Research personnel;Secondary dwellings;1,493.6
Personnel in R&D in biotechnology (FTE): Research personnel;Tool;1,692.1
Personnel in R&D in biotechnology (FTE): Technical and auxiliary personnel;Total;5,185.9
Personnel in R&D in biotechnology (FTE): Technical and auxiliary personnel;Main;2,232.0
Personnel in R&D in biotechnology (FTE): Technical and auxiliary personnel;Secondary dwellings;923.7
Personnel in R&D in biotechnology (FTE): Technical and auxiliary personnel;Tool;2,030.3
Personnel in R&D in biotechnology (FTE). Women;Total;6,539.7
Personnel in R&D in biotechnology (FTE). Women;Main;3,168.1
Personnel in R&D in biotechnology (FTE). Women;Secondary dwellings;1,378.1
Personnel in R&D in biotechnology (FTE). Women;Tool;1,993.6
Personnel in R&D in biotechnology (FTE). Women: Research personnel;Total;3,455.7
Personnel in R&D in biotechnology (FTE). Women: Research personnel;Main;1,734.1
Personnel in R&D in biotechnology (FTE). Women: Research personnel;Secondary dwellings;839.4
Personnel in R&D in biotechnology (FTE). Women: Research personnel;Tool;882.2
Personnel in R&D in biotechnology (FTE). Women: Technical and auxiliary personnel;Total;3,084.0
Personnel in R&D in biotechnology (FTE). Women: Technical and auxiliary personnel;Main;1,434.0
Personnel in R&D in biotechnology (FTE). Women: Technical and auxiliary personnel;Secondary dwellings;538.7
Personnel in R&D in biotechnology (FTE). Women: Technical and auxiliary personnel;Tool;1,111.4
Internal expenditure on R&D (thousands of euros);Total;1,038,582
Internal expenditure on R&D (thousands of euros);Main;519,104
Internal expenditure on R&D (thousands of euros);Secondary dwellings;204,849
Internal expenditure on R&D (thousands of euros);Tool;314,630
1) By nature of the expense: Current expenses;Total;940,091
1) By nature of the expense: Current expenses;Main;466,051
1) By nature of the expense: Current expenses;Secondary dwellings;179,259
1) By nature of the expense: Current expenses;Tool;294,780
1.1) Remuneration to research personnel;Total;321,570
1.1) Remuneration to research personnel;Main;164,629
1.1) Remuneration to research personnel;Secondary dwellings;73,301
1.1) Remuneration to research personnel;Tool;83,640
1.2) Remuneration to technicians and auxiliary personnel;Total;194,836
1.2) Remuneration to technicians and auxiliary personnel;Main;85,747
1.2) Remuneration to technicians and auxiliary personnel;Secondary dwellings;33,173
1.2) Remuneration to technicians and auxiliary personnel;Tool;75,916
1.3) Other current expenses;Total;423,685
1.3) Other current expenses;Main;215,675
1.3) Other current expenses;Secondary dwellings;72,786
1.3) Other current expenses;Tool;135,225
2) By nature of the expense: Capital expenses;Total;98,492
2) By nature of the expense: Capital expenses;Main;53,052
2) By nature of the expense: Capital expenses;Secondary dwellings;25,589
2) By nature of the expense: Capital expenses;Tool;19,850
2.1) Land and buildings;Total;10,199
2.1) Land and buildings;Main;5,434
2.1) Land and buildings;Secondary dwellings;2,616
2.1) Land and buildings;Tool;2,149
2.2) Equipment and instruments;Total;72,584
2.2) Equipment and instruments;Main;36,725
2.2) Equipment and instruments;Secondary dwellings;20,086
2.2) Equipment and instruments;Tool;15,773
2.3) Acquisition of specific R+D software;Total;5,721
2.3) Acquisition of specific R+D software;Main;2,513
2.3) Acquisition of specific R+D software;Secondary dwellings;2,103
2.3) Acquisition of specific R+D software;Tool;1,104
2.4) Otros productos de propiedad intelectual específicos para I+D;Total;9,987
2.4) Otros productos de propiedad intelectual específicos para I+D;Main;8,379
2.4) Otros productos de propiedad intelectual específicos para I+D;Secondary dwellings;784
2.4) Otros productos de propiedad intelectual específicos para I+D;Tool;823
1.1) By origin of the funds: Own funds;Total;711,488
1.1) By origin of the funds: Own funds;Main;314,308
1.1) By origin of the funds: Own funds;Secondary dwellings;155,688
1.1) By origin of the funds: Own funds;Tool;241,492
1.2) By origin of the funds: From companies;Total;121,738
1.2) By origin of the funds: From companies;Main;80,154
1.2) By origin of the funds: From companies;Secondary dwellings;10,983
1.2) By origin of the funds: From companies;Tool;30,601
1.3) By origin of the funds: Public Administration funds;Total;107,477
1.3) By origin of the funds: Public Administration funds;Main;61,083
1.3) By origin of the funds: Public Administration funds;Secondary dwellings;16,108
1.3) By origin of the funds: Public Administration funds;Tool;30,285
1.4) By origin of the funds: From Universities;Total;192
1.4) By origin of the funds: From Universities;Main;68
1.4) By origin of the funds: From Universities;Secondary dwellings;14
1.4) By origin of the funds: From Universities;Tool;111
1.5) By origin of the funds: From non profit private institutions;Total;10,756
1.5) By origin of the funds: From non profit private institutions;Main;9,444
1.5) By origin of the funds: From non profit private institutions;Secondary dwellings;0
1.5) By origin of the funds: From non profit private institutions;Tool;1,312
1.6) By origin of the funds: Foreign funds;Total;86,931
1.6) By origin of the funds: Foreign funds;Main;54,046
1.6) By origin of the funds: Foreign funds;Secondary dwellings;22,055
1.6) By origin of the funds: Foreign funds;Tool;10,829
Purchase of R&D services in biotechnology (thousands of euros);Total;145,557
Purchase of R&D services in biotechnology (thousands of euros);Main;105,405
Purchase of R&D services in biotechnology (thousands of euros);Secondary dwellings;16,127
Purchase of R&D services in biotechnology (thousands of euros);Tool;24,025
Purchase of R&D services in biotechnology (thousands of euros): In Spain;Total;95,915
Purchase of R&D services in biotechnology (thousands of euros): In Spain;Main;74,486
Purchase of R&D services in biotechnology (thousands of euros): In Spain;Secondary dwellings;14,004
Purchase of R&D services in biotechnology (thousands of euros): In Spain;Tool;7,425
Purchase of R&D services in biotechnology (thousands of euros): Abroad;Total;49,642
Purchase of R&D services in biotechnology (thousands of euros): Abroad;Main;30,919
Purchase of R&D services in biotechnology (thousands of euros): Abroad;Secondary dwellings;2,123
Purchase of R&D services in biotechnology (thousands of euros): Abroad;Tool;16,600
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital;Total;40.2
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital;Main;49.4
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital;Secondary dwellings;39.8
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital;Tool;30.4
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information;Total;13.2
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information;Main;12.5
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information;Secondary dwellings;15.9
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information;Tool;12.7
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources;Total;19.0
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources;Main;21.5
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources;Secondary dwellings;20.0
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources;Tool;15.7
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain;Total;11.5
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain;Main;10.4
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain;Secondary dwellings;15.1
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain;Tool;11.1
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets;Total;15.9
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets;Main;16.1
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets;Secondary dwellings;23.5
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets;Tool;12.1
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and sales channels;Total;17.0
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and sales channels;Main;20.6
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and sales channels;Secondary dwellings;19.3
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and sales channels;Tool;11.9
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception;Total;16.4
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception;Main;16.3
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception;Secondary dwellings;23.1
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception;Tool;13.6
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements;Total;40.5
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements;Main;46.9
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements;Secondary dwellings;44.1
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements;Tool;31.9
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost;Total;55.0
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost;Main;65.2
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost;Secondary dwellings;55.1
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost;Tool;43.8
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting;Total;21.9
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting;Main;24.5
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting;Secondary dwellings;25.0
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting;Tool;17.6
% Companies with income of an international origin related to biotechnological activities;Total;23.5
% Companies with income of an international origin related to biotechnological activities;Main;33.3
% Companies with income of an international origin related to biotechnological activities;Secondary dwellings;19.8
% Companies with income of an international origin related to biotechnological activities;Tool;14.4
% Turnover representing income of an international origin related to biotechnological activities;Total;1.9
% Turnover representing income of an international origin related to biotechnological activities;Main;12.1
% Turnover representing income of an international origin related to biotechnological activities;Secondary dwellings;1.2
% Turnover representing income of an international origin related to biotechnological activities;Tool;1.3
% Income of an international origin related to biotechnological activities distributed in: Income received from the EU;Total;61.6
% Income of an international origin related to biotechnological activities distributed in: Income received from the EU;Main;44.0
% Income of an international origin related to biotechnological activities distributed in: Income received from the EU;Secondary dwellings;79.9
% Income of an international origin related to biotechnological activities distributed in: Income received from the EU;Tool;60.4
% Income of an international origin related to biotechnological activities distributed in: Income received from other countries;Total;38.4
% Income of an international origin related to biotechnological activities distributed in: Income received from other countries;Main;56.0
% Income of an international origin related to biotechnological activities distributed in: Income received from other countries;Secondary dwellings;20.1
% Income of an international origin related to biotechnological activities distributed in: Income received from other countries;Tool;39.6
% Income of an international origin related to biotechnological activities by classification: Internacional trade in products and services;Total;87.6
% Income of an international origin related to biotechnological activities by classification: Internacional trade in products and services;Main;97.0
% Income of an international origin related to biotechnological activities by classification: Internacional trade in products and services;Secondary dwellings;73.4
% Income of an international origin related to biotechnological activities by classification: Internacional trade in products and services;Tool;96.5
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;Total;10.9
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;Main;1.5
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;Secondary dwellings;25.9
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;Tool;0.9
% Income of an international origin related with activities according to the classification: Operating source abroad;Total;1.1
% Income of an international origin related with activities according to the classification: Operating source abroad;Main;1.3
% Income of an international origin related with activities according to the classification: Operating source abroad;Secondary dwellings;0.7
% Income of an international origin related with activities according to the classification: Operating source abroad;Tool;1.3
% Income of an international origin related with activities according to the classification: Other;Total;0.4
% Income of an international origin related with activities according to the classification: Other;Main;0.2
% Income of an international origin related with activities according to the classification: Other;Secondary dwellings;0.0
% Income of an international origin related with activities according to the classification: Other;Tool;1.3